# RADIANT: CD101 vs Standard of Care in Subjects With Acute Vaginal Yeast Infections

> **NCT02733432** · PHASE2 · COMPLETED · sponsor: **Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)** · enrollment: 126 (actual)

## Conditions studied

- Candidiasis, Vulvovaginal
- Mycoses
- Yeast Infection
- Moniliasis, Vulvovaginal
- Vaginitis, Monilial

## Interventions

- **DRUG:** CD101 Vaginal Gel (3%)
- **DRUG:** CD101 External gel (1%)
- **DRUG:** CD101 Vaginal Ointment (6%)
- **DRUG:** CD101 External ointment (1%)
- **DRUG:** Fluconazole

## Key facts

- **NCT ID:** NCT02733432
- **Lead sponsor:** Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-06-08
- **Primary completion:** 2016-11-23
- **Final completion:** 2016-12-23
- **Target enrollment:** 126 (ACTUAL)
- **Last updated:** 2020-08-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02733432

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02733432, "RADIANT: CD101 vs Standard of Care in Subjects With Acute Vaginal Yeast Infections". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02733432. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*